NAD+ laboratory research and human clinical research

Human clinical research

The strongest recurring finding in the human NAD+ literature is a rise in blood NAD+ after oral precursors. NR produced dose-dependent increases maintained through an 8-week trial. NMN trials added walking distance and muscle insulin sensitivity to the questions being tested.

The capsule-to-blood connection persuades me under trial conditions. The leap from that measurement to a general account of healthier aging leaves me considerably less convinced. The 2025 review of precursor supplementation describes the clinical results as limited and inconsistent, with little direct information about NAD+ inside specific tissues. The missing tissue measurements deserve more attention than the size of a blood increase.

CD38 and aging

CD38 is an enzyme that consumes NAD+. Its activity rises with age, and mice lacking CD38 retained NAD+ and better mitochondrial function. Mitochondria handle much of a cell’s energy production. This experiment helps explain a loss of supply through increased consumption.

The next finding is stranger. Senescent cells, which have stopped dividing while remaining alive, can stir nearby immune cells into expressing CD38. In mouse experiments and human cell culture, that interaction connected cellular aging to NAD+ depletion; clearing senescent cells partially restored tissue NAD+ in mice.

Replacement sounded like the obvious case to investigate. These experiments turned my attention towards consumption as well. Their causal detail impresses me, although the intervention and the outcomes remain preclinical.

DNA repair and inflammatory cells

PARP1 spends NAD+ in the response to damaged DNA. Sirtuins draw on the same supply for other regulatory work. The NAD+/PARP1/SIRT1 review describes how competition for that supply can affect repair and energy metabolism in mice.

In mouse macrophages exposed to bacterial material, DNA damage activated PARP and increased NAD+ consumption. Those immune cells became dependent on the salvage pathway, which recycles nicotinamide into NAD+. Another mouse immune-cell experiment lowered NAD+ with a NAMPT inhibitor and strengthened an inflammatory response; restoring NAD+ with NMN reversed the response.

The experimental specificity persuades me. Each experiment identifies a disturbance and tests what changes when it is altered. A dish of mouse immune cells can establish that sort of mechanism. A treatment claim for human inflammation still needs a human trial.

NAD+ benefits measured in people

The Conze NR trial measured blood NAD+ and tolerability in healthy, overweight adults. The 22%, 51% and 142% blood increases corresponded to the tested amounts of 100, 300 and 1000 milligrams per day. The NR page puts those figures side by side.

Yi’s NMN trial in healthy, middle-aged adults ran for 60 days and reported greater six-minute walking distance than placebo. Yoshino’s trial in prediabetic, postmenopausal women found better muscle insulin sensitivity after 10 weeks, with no change in body composition or HbA1c, a measure of average blood sugar.

For the next study, I favor a result that connects biochemistry to function. Walking offers that connection; the insulin test offers a narrower metabolic one. Neither trial established longer human life. The NMN case is interesting precisely because its outcomes differ.

NAD IV therapy

IV delivery puts NAD+ directly into blood, bypassing the gut. Controlled evidence for health benefit is sparse. Most of the IV literature consists of small studies or accounts of previous care, and subcutaneous or intramuscular NAD+ injections have little firm pharmacokinetic evidence—evidence about what happens to a substance after administration.

I see an unresolved burden of proof here. A route into blood still leaves the questions of cellular uptake, tissue exposure and useful outcomes. The persistence passage describes the rapid early plasma clearance recorded in the IV pilot and the different time course seen with oral precursors.

NAD injection safety

Compounded NAD+ for a shot or drip needs a clinician’s prescription and has no FDA approval. The FDA recalled a prepared NAD+ shot product containing harmful bacterial waste. Endotoxin can provoke a reaction even when live bacteria are absent.

Fast infusions have been associated with chest tightness, abdominal discomfort, nausea and flushing. Those risks make the thin benefit evidence consequential. The reading list does not include the named recall notice or the IV pilot as separate entries; that documentary gap limits how far this site can trace those particular reports.